TAS::75 0849::TAS MULTIPLEXED ASSAYS FOR AKT/M TOR PATHWAY - PHASE I SBIR TOPIC

PTEN/Akt/mTORC 1&2信号通路是细胞存活、细胞生长和增殖、血管生成、细胞代谢、细胞迁移和侵袭以及葡萄糖摄取的关键调节剂。临床试验中的许多抗癌药物都针对这一途径。在第一阶段，我们将开发可靠、准确、定量和灵敏的多重杂交ELISA/qPCR检测（ELISA结合定量PCR），以准确监测暴露于抗癌药物雷帕霉素和LY 294002的细胞中的蛋白水平和途径蛋白的翻译后修饰。将生产ELISA/qPCR试剂盒并创建书面SOP。在第二阶段，我们将进一步改进该检测方法，并将其用于定量多种癌症临床样本中含有重要翻译后修饰组合的靶分子数量。灵敏、定量和标准化的多重ELISA/qPCR的可用性将有助于临床医生和研究人员分析许多疾病中的PTEN/Akt通路蛋白成员，并预测癌症治疗的疗效。

PTEN/Akt/mTORC 1&2 signal pathway is a critical regulator of cell survival, cell growth and proliferation, angiogenesis, cellular metabolism, cell migration and invasion and glucose uptake. A number of anticancer drugs in clinical trials are targeting this pathway. In Phase I, we will develop reliable, accurate, quantitative and sensitive multiplexed hybrid ELISA/qPCR assay (ELISA combined with quantitative PCR) to accurately monitor protein level and post-translational modifications of the pathway proteins in cells exposed to anticancer drugs rapamycin and LY294002. The ELISA/qPCR kit will be manufactured and written SOPs will be created. In Phase II, we will further improve the assay and use it to quantify the number of target molecules containing important combinations of post-translational modifications in clinical samples of a wide range of cancers. The availability of a sensitive, quantitative and standardized multiplexed ELISA/qPCR will aid clinicians and researchers to profile PTEN/Akt pathway protein members in a number of diseases and predict the efficacy of cancer treatment.